HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Association of single nucleotide polymorphisms in the genes ATM, GSTP1, SOD2, TGFB1, XPD and XRCC1 with risk of severe erythema after breast conserving radiotherapy.

AbstractPURPOSE:
To examine the association of polymorphisms in ATM (codon 158), GSTP1 (codon 105), SOD2 (codon 16), TGFB1 (position -509), XPD (codon 751), and XRCC1 (codon 399) with the risk of severe erythema after breast conserving radiotherapy.
METHODS AND MATERIALS:
Retrospective analysis of 83 breast cancer patients treated with breast conserving radiotherapy. A total dose of 50.4 Gy was administered, applying 1.8 Gy/fraction within 42 days. Erythema was evaluated according to the Radiation Therapy Oncology Group (RTOG) score. DNA was extracted from blood samples and polymorphisms were determined using either the Polymerase Chain Reaction based Restriction-Fragment-Length-Polymorphism (PCR-RFL) technique or Matrix-Assisted-Laser-Desorption/Ionization -Time-Of-Flight-Mass-Spectrometry (MALDI-TOF). Relative excess heterozygosity (REH) was investigated to check compatibility of genotype frequencies with Hardy-Weinberg equilibrium (HWE). In addition, p-values from the standard exact HWE lack of fit test were calculated using 100,000 permutations. HWE analyses were performed using R.
RESULTS:
Fifty-six percent (46/83) of all patients developed erythema of grade 2 or 3, with this risk being higher for patients with large breast volume (odds ratio, OR = 2.55, 95% confidence interval, CI: 1.03-6.31, p = 0.041). No significant association between SNPs and risk of erythema was found when all patients were considered. However, in patients with small breast volume the TGFB1 SNP was associated with erythema (p = 0.028), whereas the SNP in XPD showed an association in patients with large breast volume (p = 0.046). A risk score based on all risk alleles was neither significant in all patients nor in patients with small or large breast volume. Risk alleles of most SNPs were different compared to a previously identified risk profile for fibrosis.
CONCLUSIONS:
The genetic risk profile for erythema appears to be different for patients with small and larger breast volume. This risk profile seems to be specific for erythema as compared to a risk profile for fibrosis.
AuthorsAnnette Raabe, Katharina Derda, Sebastian Reuther, Silke Szymczak, Kerstin Borgmann, Ulrike Hoeller, Andreas Ziegler, Cordula Petersen, Ekkehard Dikomey
JournalRadiation oncology (London, England) (Radiat Oncol) Vol. 7 Pg. 65 (Apr 26 2012) ISSN: 1748-717X [Electronic] England
PMID22537351 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Cell Cycle Proteins
  • DNA-Binding Proteins
  • TGFB1 protein, human
  • Transforming Growth Factor beta1
  • Tumor Suppressor Proteins
  • X-ray Repair Cross Complementing Protein 1
  • XRCC1 protein, human
  • Superoxide Dismutase
  • superoxide dismutase 2
  • GSTP1 protein, human
  • Glutathione S-Transferase pi
  • ATM protein, human
  • Ataxia Telangiectasia Mutated Proteins
  • Protein Serine-Threonine Kinases
  • Xeroderma Pigmentosum Group D Protein
  • ERCC2 protein, human
Topics
  • Adult
  • Aged
  • Aged, 80 and over
  • Ataxia Telangiectasia Mutated Proteins
  • Breast Neoplasms (genetics, radiotherapy)
  • Carcinoma (genetics, radiotherapy)
  • Cell Cycle Proteins (genetics)
  • DNA-Binding Proteins (genetics)
  • Erythema (etiology, genetics)
  • Female
  • Genetic Association Studies
  • Genetic Predisposition to Disease
  • Glutathione S-Transferase pi (genetics)
  • Humans
  • Middle Aged
  • Polymorphism, Single Nucleotide (physiology)
  • Protein Serine-Threonine Kinases (genetics)
  • Radiation Injuries (etiology, genetics)
  • Retrospective Studies
  • Risk Factors
  • Severity of Illness Index
  • Superoxide Dismutase (genetics)
  • Transforming Growth Factor beta1 (genetics)
  • Tumor Suppressor Proteins (genetics)
  • X-ray Repair Cross Complementing Protein 1
  • Xeroderma Pigmentosum Group D Protein (genetics)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: